{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T19:27:25Z","timestamp":1771270045454,"version":"3.50.1"},"reference-count":57,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n<jats:title>Abstract:<\/jats:title>\n<jats:p>Nicotine dependence has deleterious neurological impacts. Previous studies found an association\nbetween cigarette smoking and accelerating age-related thinning of the brain's cortex and subsequent\ncognitive decline. Smoking is considered the third most common risk factor for dementia,\nwhich prompted the inclusion of smoking cessation in dementia prevention strategies. Traditional\npharmacologic options for smoking cessation include nicotine transdermal patches, bupropion and\nvarenicline. However, based on smokers\u2019 genetic makeup, pharmacogenetics can be used to develop\nnovel therapies to replace these traditional approaches. Genetic variability of cytochrome P450 2A6\nhas a major impact on smokers\u2019 behavior and their response to quitting therapies. Gene polymorphism\nin nicotinic acetylcholine receptor subunits also has a great influence on the ability to quit smoking. In\naddition, polymorphism of certain nicotinic acetylcholine receptors was found to affect the risk of dementia\nand the impact of tobacco smoking on the development of Alzheimer's disease. Nicotine dependence\ninvolves the activation of pleasure response through the stimulation of dopamine release.\nCentral dopamine receptors, catechol-o-methyltransferase and the dopamine transporter protein, regulate\nsynaptic dopamine levels. The genes of these molecules are potential targets for novel smoking\ncessation drugs. Pharmacogenetic studies of smoking cessation also investigated other molecules, such\nas ANKK1 and dopamine-beta-hydroxylase (DBH). In this perspective article, we aim to highlight the\npromising role of pharmacogenetics in the development of effective drugs for smoking cessation,\nwhich can increase the success rate of smoking quitting plans and ultimately reduce the incidence of\nneurodegeneration and dementia.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527322666230220121655","type":"journal-article","created":{"date-parts":[[2023,2,20]],"date-time":"2023-02-20T10:56:54Z","timestamp":1676890614000},"page":"2-8","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nicotine Abuse and Neurodegeneration: Novel Pharmacogenetic Targets\nto Aid Quitting and Reduce the Risk of Dementia"],"prefix":"10.2174","volume":"23","author":[{"given":"Fatimah","family":"Almahasneh","sequence":"first","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Romany H.","family":"Gerges","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan"},{"name":"Department of\nPharmacology, Faculty of Medicine, Assiut University, Assiut, Egypt"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ejlal","family":"Abu-El-Rub","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramada R.","family":"Khasawneh","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Faculty of Medicine, Yarmouk University, Irbid, Jordan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.24875\/RIC.18002629","volume":"71","author":"Garc\u00eda-G\u00f3mez L.","year":"2019","unstructured":"Garc\u00eda-G\u00f3mez L.; Hern\u00e1ndez-P\u00e9rez A.; No\u00e9-D\u00edaz V.; Riesco-Miranda J.A.; Jim\u00e9nez-Ruiz C.; Smoking cessation treatments: Current psychological and pharmacological options. Rev Invest Clin 2019,71(1),7-16","journal-title":"Rev Invest Clin"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1016\/j.jalz.2014.04.009","volume":"10","author":"Durazzo T.C.","year":"2014","unstructured":"Durazzo T.C.; Mattsson N.; Weiner M.W.; Smoking and increased Alzheimer\u2019s disease risk: A review of potential mechanisms. Alzheimers Dement 2014,10(3S),S122-S145","journal-title":"Alzheimers Dement"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1080\/17460441.2018.1458090","volume":"13","author":"Jordan C.J.","year":"2018","unstructured":"Jordan C.J.; Xi Z-X.; Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov 2018,13(7),671-683","journal-title":"Expert Opin Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fpsyt.2013.00029","volume":"4","author":"Hendrickson L.M.","year":"2013","unstructured":"Hendrickson L.M.; Guildford M.J.; Tapper A.R.; Neuronal nicotinic acetylcholine receptors: Common molecular substrates of nicotine and alcohol dependence. Front Psychiatry 2013,4,29","journal-title":"Front Psychiatry"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/BF00167110","volume":"40","author":"Le Nov\u00e8re N.","year":"1995","unstructured":"Le Nov\u00e8re N.; Changeux J.P.; Molecular evolution of the nicotinic acetylcholine receptor: An example of multigene family in excitable cells. J Mol Evol 1995,40(2),155-172","journal-title":"J Mol Evol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"609005","DOI":"10.3389\/fnins.2020.609005","volume":"14","author":"Ho T.N.T.","year":"2020","unstructured":"Ho T.N.T.; Abraham N.; Lewis R.J.; Structure-function of neuronal nicotinic acetylcholine receptor inhibitors derived from natural toxins. Front Neurosci 2020,14,609005","journal-title":"Front Neurosci"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1152\/physrev.00015.2008","volume":"89","author":"Albuquerque E.X.","year":"2009","unstructured":"Albuquerque E.X.; Pereira E.F.R.; Alkondon M.; Rogers S.W.; Mammalian nicotinic acetylcholine receptors: From structure to function. Physiol Rev 2009,89(1),73-120","journal-title":"Physiol Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/10673220490910844","volume":"12","author":"Adinoff B.","year":"2004","unstructured":"Adinoff B.; Neurobiologic processes in drug reward and addiction. Harv Rev Psychiatry 2004,12(6),305-320","journal-title":"Harv Rev Psychiatry"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-019-0299-4","volume":"41","author":"Xiao C.","year":"2020","unstructured":"Xiao C.; Zhou C.; Jiang J.; Yin C.; Neural circuits and nicotinic acetylcholine receptors mediate the cholinergic regulation of midbrain dopaminergic neurons and nicotine dependence. Acta Pharmacol Sin 2020,41(1),1-9","journal-title":"Acta Pharmacol Sin"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2217\/pgs-2018-0023","volume":"19","author":"Salloum N.C.","year":"2018","unstructured":"Salloum N.C.; Buchalter E.L.F.; Chanani S.; From genes to treatments: A systematic review of the pharmacogenetics in smoking cessation. Pharmacogenomics 2018,19(10),861-871","journal-title":"Pharmacogenomics"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/FPC.0b013e32835cdabd","volume":"23","author":"Bergen A.W.","year":"2013","unstructured":"Bergen A.W.; Javitz H.S.; Krasnow R.; Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenet Genomics 2013,23(2),94-103","journal-title":"Pharmacogenet Genomics"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.drugalcdep.2015.06.022","volume":"154","author":"Chen L.S.","year":"2015","unstructured":"Chen L.S.; Baker T.B.; Jorenby D.; Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation. Drug Alcohol Depend 2015,154,278-282","journal-title":"Drug Alcohol Depend"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1002\/ajmg.b.30919","volume":"150B","author":"Chen X.","year":"2009","unstructured":"Chen X.; Chen J.; Williamson V.S.; Variants in nicotinic acetylcholine receptors \u03b15 and \u03b13 increase risks to nicotine dependence. Am J Med Genet B Neuropsychiatr Genet 2009,150B(7),926-933","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1111\/add.12353","volume":"109","author":"Chen L.S.","year":"2014","unstructured":"Chen L.S.; Bloom A.J.; Baker T.B.; Pharmacotherapy effects on smoking cessation vary with nicotine metabolism gene (CYP2A6). Addiction 2014,109(1),128-137","journal-title":"Addiction"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/ng.571","volume":"42","year":"2010","unstructured":"Genome-wide meta-analyses identify multiple loci associated with smoking behavior. Nat Genet Tobacco and Genetics Consortium2010,42(5),441-447","journal-title":"Nat Genet"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3389\/fgene.2015.00046","volume":"6","author":"Rocha Santos J.","year":"2015","unstructured":"Rocha Santos J.; Tomaz P.R.X.; Issa J.S.; CHRNA4 rs1044396 is associated with smoking cessation in varenicline therapy. Front Genet 2015,6,46","journal-title":"Front Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11010-006-9333-1","volume":"297","author":"Barr J.","year":"2007","unstructured":"Barr J.; Sharma C.S.; Sarkar S.; Nicotine induces oxidative stress and activates nuclear transcription factor kappa B in rat mesencephalic cells. Mol Cell Biochem 2007,297(1-2),93-99","journal-title":"Mol Cell Biochem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1615\/JEnvPathToxOncol.v24.i3.80","volume":"24","author":"Anbarasi K.","year":"2005","unstructured":"Anbarasi K.; Vani G.; Devi C.S.S.; Protective effect of bacoside A on cigarette smoking-induced brain mitochondrial dysfunction in rats. J Environ Pathol Toxicol Oncol 2005,24(3),225-234","journal-title":"J Environ Pathol Toxicol Oncol"},{"key":"ref=19","first-page":"BR218","volume":"16","author":"Rueff-Barroso C.R.","year":"2010","unstructured":"Rueff-Barroso C.R.; Trajano E.T.; Alves J.N.; Organ-related cigarette smoke-induced oxidative stress is strain-dependent. Med Sci Monit 2010,16(7),BR218-BR226","journal-title":"Med Sci Monit"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1046\/j.1471-4159.2002.00874.x","volume":"81","author":"Nordberg A.","year":"2002","unstructured":"Nordberg A.; Hellstr\u00f6m-Lindahl E.; Lee M.; Chronic nicotine treatment reduces \u03b2-amyloidosis in the brain of a mouse model of Alzheimer\u2019s disease (APPsw). J Neurochem 2002,81(3),655-658","journal-title":"J Neurochem"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3233\/JAD-2011-102136","volume":"24","author":"Echeverria V.","year":"2011","unstructured":"Echeverria V.; Zeitlin R.; Burgess S.; Cotinine reduces amyloid-\u03b2 aggregation and improves memory in Alzheimer\u2019s disease mice. J Alzheimers Dis 2011,24(4),817-835","journal-title":"J Alzheimers Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/ana.20009","volume":"55","author":"Klunk W.E.","year":"2004","unstructured":"Klunk W.E.; Engler H.; Nordberg A.; Imaging brain amyloid in Alzheimer\u2019s disease with Pittsburgh Compound-B. Ann Neurol 2004,55(3),306-319","journal-title":"Ann Neurol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"27231","DOI":"10.1038\/srep27231","volume":"6","author":"Weng P.H.","year":"2016","unstructured":"Weng P.H.; Chen J.H.; Chen T.F.; CHRNA7 polymorphisms and dementia risk: Interactions with apolipoprotein \u03b54 and cigarette smoking. Sci Rep 2016,6(1),27231","journal-title":"Sci Rep"},{"key":"ref=24","first-page":"1179","volume":"18","author":"Russo P.","year":"2017","unstructured":"Russo P.; Kisialiou A.; Moroni R.; Prinzi G.; Fini M.; Effect of Genetic Polymorphisms (SNPs) in CHRNA7 Gene on Response to Acetylcholinesterase Inhibitors (AChEI) in Patients with Alzheimer\u2019s Disease. Curr Drug Targets 2017,18(10),1179-1190","journal-title":"Curr Drug Targets"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"e84059","DOI":"10.1371\/journal.pone.0084059","volume":"8","author":"Weng P.H.","year":"2013","unstructured":"Weng P.H.; Chen J.H.; Chen T.F.; CHRNA7 polymorphisms and response to cholinesterase inhibitors in Alzheimer\u2019s disease. PLoS One 2013,8(12),e84059","journal-title":"PLoS One"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1046\/j.1360-0443.2003.00295.x","volume":"98","author":"Li M.D.","year":"2003","unstructured":"Li M.D.; Cheng R.; Ma J.Z.; Swan G.E.; A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. Addiction 2003,98(1),23-31","journal-title":"Addiction"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1146\/annurev.pharmtox.47.120505.105214","volume":"47","author":"Dani J.A.","year":"2007","unstructured":"Dani J.A.; Bertrand D.; Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 2007,47(1),699-729","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s00359-008-0368-5","volume":"194","author":"Zhu H.","year":"2008","unstructured":"Zhu H.; Clemens S.; Sawchuk M.; Hochman S.; Unaltered D1, D2, D4, and D5 dopamine receptor mRNA expression and distribution in the spinal cord of the D3 receptor knockout mouse. J Comp Physiol A Neuroethol Sens Neural Behav Physiol 2008,194(11),957-962","journal-title":"J Comp Physiol A Neuroethol Sens Neural Behav Physiol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2217\/pgs.13.246","volume":"15","author":"Herman A.I.","year":"2014","unstructured":"Herman A.I.; DeVito E.E.; Jensen K.P.; Sofuoglu M.; Pharmacogenetics of nicotine addiction: Role of dopamine. Pharmacogenomics 2014,15(2),221-234","journal-title":"Pharmacogenomics"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1080\/14622200310001615295","volume":"5","author":"Murphy M.","year":"2003","unstructured":"Murphy M.; Johnstone E.; Griffiths S-E.; Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome? Nicotine Tob Res 2003,5(6),935-942","journal-title":"Nicotine Tob Res"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1080\/14622200701705027","volume":"9","author":"David S.P.","year":"2007","unstructured":"David S.P.; Strong D.R.; Munaf\u00f2 M.R.; Bupropion efficacy for smoking cessation is influenced by the DRD2 Taq1A polymorphism: analysis of pooled data from two clinical trials. Nicotine Tob Res 2007,9(12),1251-1257","journal-title":"Nicotine Tob Res"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/sj.tpj.6500281","volume":"5","author":"Swan G.E.","year":"2005","unstructured":"Swan G.E.; Valdes A.M.; Ring H.Z.; Dopamine receptor DRD2 genotype and smoking cessation outcome following treatment with bupropion SR. Pharmacogenomics J 2005,5(1),21-29","journal-title":"Pharmacogenomics J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1086\/420854","volume":"74","author":"Wang E.","year":"2004","unstructured":"Wang E.; Ding Y.C.; Flodman P.; The genetic architecture of selection at the human dopamine receptor D4 (DRD4) gene locus. Am J Hum Genet 2004,74(5),931-944","journal-title":"Am J Hum Genet"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/sj.tpj.6500447","volume":"8","author":"David S.P.","year":"2008","unstructured":"David S.P.; Munaf\u00f2 M.R.; Murphy M F G.; Proctor M.; Walton R.T.; Johnstone E.C.; Genetic variation in the dopamine D4 receptor (DRD4) gene and smoking cessation: Follow-up of a randomised clinical trial of transdermal nicotine patch. Pharmacogenomics J 2008,8(2),122-128","journal-title":"Pharmacogenomics J"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1080\/14622200410001676396","volume":"6","author":"Tomlinson G.","year":"2004","unstructured":"Tomlinson G.; Tsoh J.; De Moor C.; The effects of the DRD2 polymorphism on smoking cessation and negative affect: Evidence for a pharmacogenetic effect on mood. Nicotine Tob Res 2004,6(2),229-239","journal-title":"Nicotine Tob Res"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/ajmg.b.10948","volume":"114","author":"Mill J.","year":"2002","unstructured":"Mill J.; Asherson P.; Browes C.; D\u2019Souza U.; Craig I.; Expression of the dopamine transporter gene is regulated by the 3? UTR VNTR: Evidence from brain and lymphocytes using quantitative RT-PCR. Am J Med Genet 2002,114(8),975-979","journal-title":"Am J Med Genet"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.biopsych.2006.04.030","volume":"61","author":"Berrettini W.H.","year":"2007","unstructured":"Berrettini W.H.; Wileyto E.P.; Epstein L.; Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence. Biol Psychiatry 2007,61(1),111-118","journal-title":"Biol Psychiatry"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00008571-200402000-00002","volume":"14","author":"Johnstone E.C.","year":"2004","unstructured":"Johnstone E.C.; Yudkin P.L.; Hey K.; Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch. Pharmacogenetics 2004,14(2),83-90","journal-title":"Pharmacogenetics"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.tics.2018.12.006","volume":"23","author":"Ott T.","year":"2019","unstructured":"Ott T.; Nieder A.; Dopamine and cognitive control in prefrontal cortex. Trends Cogn Sci 2019,23(3),213-234","journal-title":"Trends Cogn Sci"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1016\/j.neuron.2015.12.029","volume":"89","author":"Westbrook A.","year":"2016","unstructured":"Westbrook A.; Braver T.S.; Dopamine does double duty in motivating cognitive effort. Neuron 2016,89(4),695-710","journal-title":"Neuron"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S0301-0082(03)00085-6","volume":"69","author":"Jay T.M.","year":"2003","unstructured":"Jay T.M.; Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 2003,69(6),375-390","journal-title":"Prog Neurobiol"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.neuron.2010.02.006","volume":"65","author":"Axmacher N.","year":"2010","unstructured":"Axmacher N.; Cohen M.X.; Fell J.; Intracranial EEG correlates of expectancy and memory formation in the human hippocampus and nucleus accumbens. Neuron 2010,65(4),541-549","journal-title":"Neuron"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.neuron.2005.05.002","volume":"46","author":"Lisman J.E.","year":"2005","unstructured":"Lisman J.E.; Grace A.A.; The hippocampal-VTA loop: Controlling the entry of information into long-term memory. Neuron 2005,46(5),703-713","journal-title":"Neuron"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"12032","DOI":"10.1523\/JNEUROSCI.3446-08.2008","volume":"28","author":"Takahashi H.","year":"2008","unstructured":"Takahashi H.; Kato M.; Takano H.; Differential contributions of prefrontal and hippocampal dopamine D(1) and D(2) receptors in human cognitive functions. J Neurosci 2008,28(46),12032-12038","journal-title":"J Neurosci"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.neubiorev.2021.10.011","volume":"131","author":"Castillo D\u00edaz F.","year":"2021","unstructured":"Castillo D\u00edaz F.; Caffino L.; Fumagalli F.; Bidirectional role of dopamine in learning and memory-active forgetting. Neurosci Biobehav Rev 2021,131,953-963","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.3389\/fnagi.2019.00175","volume":"11","author":"Pan X.","year":"2019","unstructured":"Pan X.; Kaminga A.C.; Wen S.W.; Wu X.; Acheampong K.; Liu A.; Dopamine and dopamine receptors in alzheimer\u2019s disease: A systematic review and network meta-analysis. Front Aging Neurosci 2019,11,175","journal-title":"Front Aging Neurosci"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"14727","DOI":"10.1038\/ncomms14727","volume":"8","author":"Nobili A.","year":"2017","unstructured":"Nobili A.; Latagliata E.C.; Viscomi M.T.; Dopamine neuronal loss contributes to memory and reward dysfunction in a model of Alzheimer\u2019s disease. Nat Commun 2017,8(1),14727","journal-title":"Nat Commun"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1212\/WNL.43.2.293","volume":"43","author":"Brenner D.E.","year":"1993","unstructured":"Brenner D.E.; Kukull W.A.; van Belle G.; Relationship between cigarette smoking and Alzheimer\u2019s disease in a population-based case-control study. Neurology 1993,43(2),293-300","journal-title":"Neurology"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/(SICI)1099-1166(199703)12:3<295:AID-GPS476>3.0.CO;2-3","volume":"12","author":"Salib E.","year":"1997","unstructured":"Salib E.; Hillier V.; A case-control study of smoking and Alzheimer\u2019s disease. Int J Geriatr Psychiatry 1997,12(3),295-300","journal-title":"Int J Geriatr Psychiatry"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3233\/JAD-2010-1240","volume":"19","author":"Cataldo J.K.","year":"2010","unstructured":"Cataldo J.K.; Prochaska J.J.; Glantz S.A.; Cigarette smoking is a risk factor for Alzheimer\u2019s Disease: An analysis controlling for tobacco industry affiliation. J Alzheimers Dis 2010,19(2),465-480","journal-title":"J Alzheimers Dis"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1046\/j.1360-0443.2002.00016.x","volume":"97","author":"Almeida O.P.","year":"2002","unstructured":"Almeida O.P.; Hulse G.K.; Lawrence D.; Flicker L.; Smoking as a risk factor for Alzheimer\u2019s disease: Contrasting evidence from a systematic review of case-control and cohort studies. Addiction 2002,97(1),15-28","journal-title":"Addiction"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14622200701767811","volume":"10","author":"deBry S.","year":"2008","unstructured":"deBry S.; Tiffany S.; Tobacco-Induced Neurotoxicity Of Adolescent Cognitive Development (TINACD): A proposed model for the development of impulsivity in nicotine dependence. Nicotine Tob Res 2008,10(1),11-25","journal-title":"Nicotine Tob Res"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.euroneuro.2017.07.007","volume":"27","author":"Akkermans S.E.A.","year":"2017","unstructured":"Akkermans S.E.A.; van Rooij D.; Rommelse N.; Effect of tobacco smoking on frontal cortical thickness development: A longitudinal study in a mixed cohort of ADHD-affected and -unaffected youth. Eur Neuropsychopharmacol 2017,27(10),1022-1031","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.drugalcdep.2018.08.009","volume":"192","author":"Durazzo T.C.","year":"2018","unstructured":"Durazzo T.C.; Meyerhoff D.J.; Yoder K.K.; Cigarette smoking is associated with cortical thinning in anterior frontal regions, insula and regions showing atrophy in early Alzheimer\u2019s Disease. Drug Alcohol Depend 2018,192,277-284","journal-title":"Drug Alcohol Depend"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1038\/mp.2014.187","volume":"20","author":"Karama S.","year":"2015","unstructured":"Karama S.; Ducharme S.; Corley J.; Cigarette smoking and thinning of the brain\u2019s cortex. Mol Psychiatry 2015,20(6),778-785","journal-title":"Mol Psychiatry"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"17562864221092566","DOI":"10.1177\/17562864221092566","volume":"15","author":"Wang C.","year":"2022","unstructured":"Wang C.; Zhou C.; Guo T.; Huang P.; Xu X.; Zhang M.; Association between cigarette smoking and Parkinson\u2019s disease: A neuroimaging study. Ther Adv Neurol Disord 2022,15,17562864221092566","journal-title":"Ther Adv Neurol Disord"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3892\/mmr.2021.12037","volume":"23","author":"Alhowail A.","year":"2021","unstructured":"Alhowail A.; Molecular insights into the benefits of nicotine on memory and cognition. Mol Med Rep 2021,23(6),398","journal-title":"Mol Med Rep"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666230220121655","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/213806\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527322666230220121655","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T12:50:53Z","timestamp":1696596653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/213806\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527322666230220121655","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2022-08-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-23","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-01-11","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}